In vitro cytotoxicity, in vivo biodistribution and antitumor activity of HPMA copolymer-5-fluorouracil conjugates

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 3, 2008, Pages 770-776

  Yuan, Fang ^a   Qin, Xuan ^a   Zhou, Dan ^a   Xiang, Qing Yu ^a   Wang, Min Ting ^a   Zhang, Zhi Rong ^a   Huang, Yuan ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

5 Fluorouracil; Antitumor drug; Cytotoxicity; Hepatoma 22; N (2 hydroxypropyl) methacrylamide copolymer

Indexed keywords

COPOLYMER; FLUOROURACIL; N (2 HYDROXYPROPYL)METHACRYLAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; CANCER MODEL; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; FEMALE; HELA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; TUMOR CELL LINE;

ACRYLAMIDES; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; FEMALE; FLUOROURACIL; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS, EXPERIMENTAL; MICE; TIME FACTORS;

EID: 54949139950     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.06.028     Document Type: Article

References (29)

1. Scherf U., Ross D.T., Waltham M., Smith L.H., Lee J.K., Tanabe L., Kohn K.W., Reinhold W.C., Myers T.G., Andrews D.T., Scudiero D.A., Eisen M.B., Sausville E.A., Pommier Y., Botstein D., Brown P.O., and Weinstein J.N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24 (2000) 236-244
2. Grem J.L. 5-Fluoropyrimidines, Cancer Chemotherapy and Biotherapy Principles and Practice. second ed. In: Chabner B.A., and Longo D.L. (Eds) (1996), Lippincott, Philadelphia, PA 149-211
3. Daher G.C., Harris B.E., and Diasio R.B. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol. Ther. 48 (1990) 189-222
4. Ringsdorf H. Structure and properties of pharmacologically active polymers. J. Polym. Sci. Polym. Symp. 51 (1975) 135-153
5. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res. 46 (1986) 6387-6392
6. Kopeček J. Soluble biomedical polymers. Polim. Med. 7 (1977) 191-221
7. Chytry V., Vrána A., and Kopeček J. Synthesis and activity of a polymer which contains insulin covalently bound on a copolymer of N-(2-hydroxypropyl) methacrylamide and N-methacryloylglycylglycine 4-nitrophenyl ester. Makromol Chem. 179 (1978) 329-336
8. Obereigner B., Burešová M., Vrána A., and Kopeček J. Preparation of polymerizable derivatives of N-(4-aminobenzenesulfonyl)-N′-butylurea. J. Polym. Sci. Polym. Symp. 66 (1979) 41-52
9. Kopeček J., Kopečková P., Minko T., and Lu Z.R. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50 (2000) 61-81
10. 6 and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J. Control. Release 61 (1999) 145-157
11. Shiah J.G., Dvorak M., Kopečková P., Sun Y., Peterson C.M., and Kopeček J. Biodistribution and antitumor efficacy of long-circulation N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin conjugates in nude mice. Eur. J. Cancer 37 (2001) 131-139
12. Huang Y., Ghandehari H., Duan Y.R., Nan A., and Zhang Z.R. HPMA copolymer-mitoxantrone conjugates for targeted cancer chemotherapy. J. Drug Deliv. Sci. Technol. 14 (2004) 187-191
13. W.W. Ten Bokkel Huinink, J. Meerum Terwogt, R. Dubbelman, L. Valkenet, M.G. Zurlo, J.H.M. Schellens, J.H. Beijnen, Phase I and pharmacokinetics study of PNU166945, a polymer formulated placlitaxel, Proceedings of the Third International Symposium on Polymer Therapeutics, London, U.K. (1998) p. 12.
14. D.J. Kerr, L.W. Seymour, C. Boivin, P. Julyan, J. Doran, M. David, D. Anderson, C. Christodolou, S. Daryani, A.M. Young, S. Hesslewood, D.R. Ferry, Phase I clinical trial of HPMA copolymers bearing doxorubicin and galactosamine. Proceedings of the Third International Symposium on Polymer Therapeutics, London, U.K. (1998) p. 23.
15. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., and Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)-methacrylamide copolymer doxorubicin]: first member of a new class of therapeutic agents-drug-polymer conjugates. Clin. Cancer Res. 5 (1999) 83-94
16. Caiolfa V.R., Zamai M., Fiorino A., Frigerio E., Pellizzoni C., d'Argy R., Ghiglieri A., Castelli M.G., Farao M., Pesenti E., Gigli M., Angelucci F., and Suarato A. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J. Control. Release 65 (2000) 105-119
17. Putnam D., and Kopeček J. Enantioselective release of 5-fluorouracil from N-(2-hydroxy-propyl)-methacrylamide based copolymers via lysosomal enzymes. Bioconjugate Chem. 6 (1995) 483-492
18. Yuan F., Chen F., Xiang Q.Y., Qin X., Zhang Z.R., and Huang Y. Synthesis and characterization of HPMA copolymer-5-FU conjugates. Chinese Chem. Lett. 19 (2008) 137-140
19. Xu H., Choi S.M., An C.S., Min Y.D., Kim K.C., Kim K.J., and Choi C.H. Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines. Biochem. Bioph. Res. Co. 328 (2005) 618-622
20. Wei Y.Q., Huang M.J., Yang L., Zhao X., Tian L., Lu Y., Shu J.M., Lu C.J., Niu T., Kang B., Mao Y.Q., Liu F., Wen Y.J., Lei S., Luo F., Zhou L.Q., Peng F., Jiang Y., Liu J.Y., Zhou H., Wang Q.R., He Q.M., Xiao F., Lou Y.Y., Xie X.J., Li Q., Wu Y., Ding Z.Y., Hu B., Hu M., and Zhang W. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc. Natl. Acad. Sci. USA 98 (2001) 11545-11550
21. n nanoparticles in tumor-bearing mice. Biochem. Pharmacol. 71 (2006) 872-881
22. Ouchi T., Tada M., Matsumoto M., Ohya Y., Hasegawa K., Arai Y., Kadowaki K., Akao S., Matsumoto T., and Suzuki S. Design of macromolecular prodrug of S-fluorouracil using N-acetylpolygalactosamine as a targeting carrier to hepatoma. React. Funct. Polym. 37 (1998) 235-244
23. Huang J., Wang J.W., Gong T., and Zhang Z.R. Synthesis and characterization of insulin-5-FU conjugate, enabling insulin as multi-drug carrier via dendritic approach. Chin. Chem. Lett. 18 (2007) 247-250
24. Corbett T.H., Griswold Jr. D.P., Roberts B.J., Peckham J.C., and Schabel Jr. F.M. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat. Rep. 60 (1978) 1471-1488
25. Salonga D., Danenberg K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D.D., Lenz H.J., Leichman C.G., Leichman L., Diasio R.B., and Danenberg P.V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6 (2000) 1322-1327
26. Ulbrich K., Šubr V., Strohalm J., Plocová D., Jelínková M., and Ři{dotless}́hová B. Polymeric drugs based on conjugates of synthetic and natural macromolecules I. Synthesis and physico-chemical characterization. J. Control. Release 64 (2000) 63-79
27. de Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., and Van Hoof F. Lysosomotropic agents. Biochem. Pharmacol. 23 (1974) 2495-2531
28. Longley D.B., Harkin D.P., and Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3 (2003) 330-338
29. Minko T., Kopečková P., and Kopeček J. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicine in a solid tumor model of ovarian carcinoma. Int. J. Cancer 86 (2000) 108-117